AHA/ACC科学声明:风险评估指导血压管理决策
该科学声明总结推荐使用PREVENT方程评估10年心血管疾病风险以指导降压治疗启动的理由,阐述新风险阈值≥7.5%的证据基础及人群层面影响,并提供将风险评估作为高血压综合管理第一步的实践建议,强调需创新策略改善指南实施与依从性。
要点
- 推荐用PREVENT方程评估10年总心血管疾病风险以指导降压启动。
- 1级高血压患者10年心血管疾病风险≥7.5%时启动降压药物治疗。
- 风险评估应作为高血压综合管理的第一步并支持医患共享决策。
核心结论
- 推荐使用PREVENT方程评估10年总心血管疾病风险以指导降压治疗启动。
- 新定义1级高血压患者启动降压治疗的10年心血管疾病风险阈值为≥7.5%。
研究设计与样本
- 美国心脏协会与美国心脏病学会联合发布的科学声明。
主要发现
- 2017年高血压指南首次纳入定量风险评估指导降压药物启动,推荐用Pooled Cohort Equations计算10年动脉粥样硬化性心血管疾病风险。
- 2025年高血压指南重申基于风险启动降压药物的总体范式,并将推荐风险模型更新为PREVENT方程,估计10年总心血管疾病风险(包括动脉粥样硬化性心血管疾病和心力衰竭)。
- 2025年高血压指南为1级高血压患者定义了启动降压治疗的新风险阈值。
关键数值与推荐
- 1级高血压患者启动降压治疗的10年心血管疾病风险阈值为≥7.5%。
临床怎么用
- 将风险评估作为高血压综合管理的第一步,支持医患共享决策。
- 可通过电子健康记录中风险评估自动化、决策支持工具等策略改善指南实施与依从性。
局限性
- 高血压知晓和治疗的剩余差距凸显需要创新策略改善基于风险的指南推荐实施与依从性。
- 需要完善风险评估以公平地改善降压药物启动、血压控制和结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Risk assessment plays a central role in the primary prevention of cardiovascular disease. The 2017 High Blood Pressure Clinical Practice Guideline incorporated quantitative risk assessment for the first time to guide the initiation of antihypertensive drug therapy and recommended calculation of 10-year risk of atherosclerotic cardiovascular disease with the Pooled Cohort Equations. Although the 2025 High Blood Pressure Guideline reaffirmed this overarching paradigm for risk-based initiation of antihypertensive drug therapy, it updated the recommended risk model to the Predicting Risk of Cardiovascular Disease Events equations, which estimate 10-year risk of total cardiovascular disease (including atherosclerotic cardiovascular disease and heart failure), and defined a new risk threshold for initiation of antihypertensive therapy in patients with stage 1 hypertension. This American Heart Association/American College of Cardiology scientific statement summarizes the rationale to recommend the use of the Predicting Risk of Cardiovascular Disease Events equations, the evidence base for the new threshold of 10-year risk of cardiovascular disease of ≥7.5%, and the population-level implications of these revised recommendations. This scientific statement also offers practical advice for implementing risk assessment as the first step in the comprehensive approach to hypertension management with shared decision-making between patients and clinicians. Remaining gaps in awareness and treatment of hypertension underscore the need for innovative strategies to improve implementation of and adherence to risk-based guideline recommendations, including automation of risk assessment in electronic health records, decision-support aids, and refinement of risk assessment, to equitably improve the initiation of antihypertensive drug therapy, blood pressure control, and outcomes.
引用
- Khan, Lloyd-Jones, Abdalla, et al. Use of Risk Assessment to Guide Decision-Making for Blood Pressure Management in the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2025. PMID: 40879587. doi:10.1016/j.jacc.2025.08.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。